414 related articles for article (PubMed ID: 22152283)
1. Pitavastatin: clinical effects from the LIVES Study.
Teramoto T
Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283
[TBL] [Abstract][Full Text] [Related]
2. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
3. Pitavastatin: an overview.
Saito Y
Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
[TBL] [Abstract][Full Text] [Related]
4. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
5. Pitavastatin - results from phase III & IV.
Betteridge J
Atheroscler Suppl; 2010 Dec; 11(3):8-14. PubMed ID: 21193153
[TBL] [Abstract][Full Text] [Related]
6. Pitavastatin in cardiometabolic disease: therapeutic profile.
Masana L
Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S2. PubMed ID: 23819752
[TBL] [Abstract][Full Text] [Related]
7. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
da Silva PM
Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
9. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Gumprecht J; Gosho M; Budinski D; Hounslow N
Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
[TBL] [Abstract][Full Text] [Related]
10. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals.
Saito Y
Vasc Health Risk Manag; 2009; 5():921-36. PubMed ID: 19997573
[TBL] [Abstract][Full Text] [Related]
11. New evidence on pitavastatin: efficacy and safety in clinical studies.
Teramoto T; Shimano H; Yokote K; Urashima M
Expert Opin Pharmacother; 2010 Apr; 11(5):817-28. PubMed ID: 20201733
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
[TBL] [Abstract][Full Text] [Related]
13. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
Liu PY; Lin LY; Lin HJ; Hsia CH; Hung YR; Yeh HI; Wu TC; Chen JY; Chien KL; Chen JW
PLoS One; 2013; 8(10):e76298. PubMed ID: 24098467
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis.
Yokote K; Shimano H; Urashima M; Teramoto T
Expert Rev Cardiovasc Ther; 2011 May; 9(5):555-62. PubMed ID: 21615316
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia.
Ose L; Budinski D; Hounslow N; Arneson V
Atherosclerosis; 2010 May; 210(1):202-8. PubMed ID: 20080236
[TBL] [Abstract][Full Text] [Related]
16. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.
Duggan ST
Drugs; 2012 Mar; 72(4):565-84. PubMed ID: 22356292
[TBL] [Abstract][Full Text] [Related]
17. Statins in cardiometabolic disease: what makes pitavastatin different?
Ginsberg H
Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S1. PubMed ID: 23819727
[TBL] [Abstract][Full Text] [Related]
18. Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.
Kakuda H; Matoba M; Nakatoh H; Nagao S; Takekoshi N
Scand J Clin Lab Invest; 2014 Jun; 74(4):285-95. PubMed ID: 24564634
[TBL] [Abstract][Full Text] [Related]
19. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
Saku K; Zhang B; Noda K;
Circ J; 2011; 75(6):1493-505. PubMed ID: 21498906
[TBL] [Abstract][Full Text] [Related]
20. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Yee LL; Wright EA
Clin Ther; 2011 Aug; 33(8):1023-42. PubMed ID: 21816477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]